Abstract:Background: Early mesoderm can be classified into Flk-1+ or PDGF receptor alpha (PDGFRα)+ population, grossly representing lateral and paraxial mesoderm, respectively. It has been demonstrated that all endothelial (EC) and hematopoietic (HPC) cells are derived from Flk-1+ cells. Although PDGFRα+ cells give rise to ECs/HPCs in in vitro ES differentiation, whether PDGFRα+ population can become hemato-endothelial lineages has not been proved in mouse embryos. Results: Using PDGFRαMerCreMer mice, PDGFRα+ early mes… Show more
“…However, these results are supported by the finding that fetal liver hematopoiesis was not affected in the Pdgfra conditional knockout embryos (Ding et al, 2013). Our data together with others (Ding et al, 2013) support the notion that the endothelial, but not the hematopoietic lineage is sensitive to the level of Pdgfra.…”
Section: Discussionmentioning
confidence: 64%
“…However, these results are supported by the finding that fetal liver hematopoiesis was not affected in the Pdgfra conditional knockout embryos (Ding et al, 2013). Our data together with others (Ding et al, 2013) support the notion that the endothelial, but not the hematopoietic lineage is sensitive to the level of Pdgfra. We propose that as Flk1 + /Pdgfra + common mesodermal progenitors progress to the Flk1 + /Pdgfra − hemato-endothelial progenitors, miR-130a further down-regulates Pdgfra expression to direct cells towards the endothelial lineage (Figure S4).…”
MicroRNAs are known to regulate critical developmental stages during embryogenesis. Here, we defined an Etv2-miR-130a cascade that regulates mesodermal specification and determination. Ablation of Dicer in the Etv2-expressing precursors resulted in altered mesodermal lineages and embryonic lethality. We identified miR-130a as a direct target of Etv2 and demonstrated its role in the segregation of bipotent hemato-endothelial progenitors towards the endothelial lineage. Gain-of-function experiments demonstrated that miR-130a promoted the endothelial program at the expense of the cardiac program without impacting the hematopoietic lineages. In contrast, CRISPR/Cas9-mediated knockout of miR-130a demonstrated a reduction of the endothelial program without affecting hematopoiesis. Mechanistically, miR-130a directly suppresses Pdgfra expression and promotes the endothelial program by blocking Pdgfra signaling. Inhibition or activation of Pdgfra signaling phenocopied the miR-130a over-expression and knockout, phenotypes, respectively. In summary, we report the function of a miRNA that specifically promotes the divergence of the hemato-endothelial progenitor to the endothelial lineage.
“…However, these results are supported by the finding that fetal liver hematopoiesis was not affected in the Pdgfra conditional knockout embryos (Ding et al, 2013). Our data together with others (Ding et al, 2013) support the notion that the endothelial, but not the hematopoietic lineage is sensitive to the level of Pdgfra.…”
Section: Discussionmentioning
confidence: 64%
“…However, these results are supported by the finding that fetal liver hematopoiesis was not affected in the Pdgfra conditional knockout embryos (Ding et al, 2013). Our data together with others (Ding et al, 2013) support the notion that the endothelial, but not the hematopoietic lineage is sensitive to the level of Pdgfra. We propose that as Flk1 + /Pdgfra + common mesodermal progenitors progress to the Flk1 + /Pdgfra − hemato-endothelial progenitors, miR-130a further down-regulates Pdgfra expression to direct cells towards the endothelial lineage (Figure S4).…”
MicroRNAs are known to regulate critical developmental stages during embryogenesis. Here, we defined an Etv2-miR-130a cascade that regulates mesodermal specification and determination. Ablation of Dicer in the Etv2-expressing precursors resulted in altered mesodermal lineages and embryonic lethality. We identified miR-130a as a direct target of Etv2 and demonstrated its role in the segregation of bipotent hemato-endothelial progenitors towards the endothelial lineage. Gain-of-function experiments demonstrated that miR-130a promoted the endothelial program at the expense of the cardiac program without impacting the hematopoietic lineages. In contrast, CRISPR/Cas9-mediated knockout of miR-130a demonstrated a reduction of the endothelial program without affecting hematopoiesis. Mechanistically, miR-130a directly suppresses Pdgfra expression and promotes the endothelial program by blocking Pdgfra signaling. Inhibition or activation of Pdgfra signaling phenocopied the miR-130a over-expression and knockout, phenotypes, respectively. In summary, we report the function of a miRNA that specifically promotes the divergence of the hemato-endothelial progenitor to the endothelial lineage.
“…This hemogenic competence of endothelial progenitors was further shown to be restricted by Runx1 silencing (Eliades et al, 2016). Interestingly, a subset of endothelial cells and hematopoietic cells located ventrally in the E10.5 AGM and a subset of endothelial cells and hematopoietic progenitor/stem cells in the E15.5 fetal liver can be derived from PDGFRα + early paraxial mesodermal cells, as shown by cell tracing in which PDGFRα + cells were labelled at E7.5-E8 by tamoxifen injections into pregnant females (Ding et al, 2013). However, PDGFRα is dispensable for the development of fetal liver hematopoiesis and P dgfra- deleted mice die from a cephalic closure defect and skeletal abnormalities (Soriano, 1997).…”
Section: Exploring the Possible Origins Of Hsc Heterogeneitymentioning
Not all hematopoietic stem cells (HSCs) are alike. They differ in their physical characteristics such as cell cycle status and cell surface marker phenotype, they respond to different extrinsic signals, and they have different lineage outputs following transplantation. The growing body of evidence that supports heterogeneity within HSCs, which constitute the most robust cell fraction at the foundation of the adult hematopoietic system, is currently of great interest and raises questions as to why HSC subtypes exist, how they are generated and whether HSC heterogeneity affects leukemogenesis or treatment options. This Review provides a developmental overview of HSC subtypes during embryonic, fetal and adult stages of hematopoiesis and discusses the possible origins and consequences of HSC heterogeneity.
“…However, the usefulness of these markers is limited by their overall poor lineage specificity. Notably, PDGFRα and VEGFR2 are dynamically expressed on several mesodermal populations including paraxial mesoderm and lateral plate mesoderm and thus are not lineage-specific markers (Ding et al, 2013;Ema et al, 2006;Motoike et al, 2003;Takebe et al, 2006). Fluorescent reporters.…”
Section: Box 1 Tools For Characterizing Psc-derived Myogenic Progenimentioning
Skeletal muscle is the largest tissue in the body and loss of its function or its regenerative properties results in debilitating musculoskeletal disorders. Understanding the mechanisms that drive skeletal muscle formation will not only help to unravel the molecular basis of skeletal muscle diseases, but also provide a roadmap for recapitulating skeletal myogenesis in vitro from pluripotent stem cells (PSCs). PSCs have become an important tool for probing developmental questions, while differentiated cell types allow the development of novel therapeutic strategies. In this Review, we provide a comprehensive overview of skeletal myogenesis from the earliest premyogenic progenitor stage to terminally differentiated myofibers, and discuss how this knowledge has been applied to differentiate PSCs into muscle fibers and their progenitors in vitro.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.